Recent Publications by Cubist Pharmaceuticals: |
Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis.
Danish studies of traffic accidents at priority intersections have shown a... | 17th November, 2009
| Alabama Infectious Disease Center Nephrology Consultants, LLC Huntsville,
| Perit Dial Int. 2009 Nov-Dec;29(6):671-3.
|
Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.
This review summarizes the in vitro and animal model data available on... | 15th October, 2009
| Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA.
| J Antimicrob Chemother. 2009 Dec;64(6):1130-8. Epub 2009 Oct 12.
DOI Direct Link |
Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
The decrease in vancomycin treatment efficacy that is accompanying... | 10th October, 2009
| Cubist Pharmaceuticals, Lexington, MA, USA.
| Lancet Infect Dis. 2009 Oct;9(10):617-24.
DOI Direct Link |
Retrospective review of the use of daptomycin for diabetic foot infections.
The increase in antibiotic resistance has led to a search for alternative... | 1st October, 2009
| Cubist Pharmaceuticals, Lexington, Massachusetts, USA.
| J Wound Care. 2009 Sep;18(9):396-400.
|
Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.
Antibiotic safety is a major determinant in osteomyelitis therapy. Limited... | 1st October, 2009
| Cubist Pharmaceuticals, Lexington, MA 02421, USA.
| J Chemother. 2009 Aug;21(4):414-20.
|
Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
BACKGROUND: Daptomycin is approved for the treatment of skin and... | 25th September, 2009
| Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA.
| Ann Pharmacother. 2009 Jul;43(7):1211-9. Epub 2009 Jul 7.
DOI Direct Link |
Daptomycin: mechanisms of action and resistance, and biosynthetic engineering.
Daptomycin is a lipopeptide antibiotic used clinically to treat infections... | 31st July, 2009
| Discovery Biology, Cubist Pharmaceuticals, Inc., 65 Hayden Avenue,
| Curr Opin Chem Biol. 2009 Apr;13(2):144-51. Epub 2009 Mar 19.
DOI Direct Link |
Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Enterococcal infections are a common cause of nosocomial bloodstream... | 26th June, 2009
| Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA.
| Int J Antimicrob Agents. 2009 Jun;33(6):543-8. Epub 2009 Feb 6.
DOI Direct Link |
Chapter 20. Biosynthesis and genetic engineering of lipopeptides in Streptomyces roseosporus.
Daptomycin is an acidic cyclic lipopeptide antibiotic approved for... | 24th June, 2009
| Cubist Pharmaceuticals Inc, Lexington, Massachusetts, USA.
| Methods Enzymol. 2009;458:511-31.
DOI Direct Link |
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.
BACKGROUND: Results from previous trials suggest that daptomycin may... | 12th May, 2009
| Clinical Research, Cubist Pharmaceuticals, Lexington, MA 02421, USA.
| Int J Clin Pract. 2009 Mar;63(3):368-75.
DOI Direct Link |
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
BACKGROUND: Methicillin-susceptible and -resistant (MRSA) Staphylococcus... | 8th May, 2009
| Cubist Pharmaceuticals, Inc., Lexington, MA 02421, USA.
| Int J Clin Pract. 2008 Sep;62(9):1455-64. Epub 2008 Jul 25.
DOI Direct Link |
Renaissance in antibacterial discovery from actinomycetes.
The soil actinomycetes have been important sources of antibiotics, but... | 31st January, 2009
| Drug Discovery and Evaluation, Cubist Pharmaceuticals, Inc., 65 Hayden
| Curr Opin Pharmacol. 2008 Oct;8(5):557-63. Epub 2008 Jun 3.
DOI Direct Link |
Non-ribosomal peptide synthetase module fusions to produce derivatives of daptomycin in Streptomyces roseosporus.
Genetic engineering has been applied to reprogramme non-ribosomal peptide... | 10th October, 2008
| Cubist Pharmaceuticals Inc., 65 Hayden Avenue, Lexington, MA 02421, USA.
| Microbiology. 2008 Sep;154(Pt 9):2872-80.
DOI Direct Link |
Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry.
AIM: To compare and contrast the characteristics and clinical outcomes of... | 1st October, 2008
| Cubist Pharmaceuticals, Inc., Lexington, MA 02421, USA.
| Int J Clin Pract. 2008 Aug;62(8):1183-7.
DOI Direct Link |
Biosynthesis and genetic engineering of lipopeptide antibiotics related to daptomycin.
Daptomycin is a clinically important antibiotic approved for the treatment... | 23rd September, 2008
| Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts
| Curr Top Med Chem. 2008;8(8):618-38.
|
